Clinical Trials
16 trialsNCT07607925 2026-05-27
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
GlaxoSmithKline
Phase 1/2 Not yet recruiting
NCT07601607 2026-05-22
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07567469 2026-05-05
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
Regeneron Pharmaceuticals
Phase 1/2 Not yet recruiting
NCT07542717 2026-04-21
ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting
NCT07535710 2026-04-17
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Shanghai Jiao Tong University School of Medicine
Phase 1/2 Not yet recruiting
NCT07510100 2026-04-03
FUMANBA-04
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07502768 2026-03-31
EpiRev-NKT
Fudan University
Phase 1/2 Not yet recruiting
NCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT07288814 2025-12-17
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT07206563 2025-10-03
Penfluridol for Relapsed/Refractory Small Cell Cancers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Not yet recruiting
NCT06281847 2025-09-18
RESOLVE AML001
Advesya SAS
Phase 1/2 Not yet recruiting
NCT07107204 2025-09-17
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
Phase 1/2 Not yet recruiting
NCT07175415 2025-09-16
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT06845241 2025-02-25
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06180499 2024-02-14
ILDTreg2
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Not yet recruiting
NCT05503888 2022-08-17
Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Not yet recruiting